A Study of Tafetinib in Chinese Patients With Advanced Solid Tumor

Inclusion Criteria

• •Adult patients with histologically confirmed advanced solid malignancies.
• •ECOG score 0-1.
• •18-65 years old.
• •Withdrawal other chemotherapy drugs more than 30 days. No nitrosoureas or mitomycin C within the previous 6 weeks.
• •Function of organs must meet the following requirements:
• •Neutrophil count ≥1500/ul;
• •AST and ALT≤1.5 times the upper limit of normal (ULN);
• •Total serum bilirubin≤1.5 times ULN;
• •Hemoglobin≥90g/L;
• •Platelet≥100000/ul;
• •The creatinine in the normal range or creatinine clearance rate ≥60ml/min;
• •Left ventricular ejection fraction (LVEF) ≥50%;
• •Females of childbearing age are required to be practicing effective contraceptive measures and to have a negative serum or urine pregnancy test before study.
• •Written informed consent is obtained.